Introduction
In the last decade, the prevalence of overweight and obesity (defined as BMI . 25 kg/m 2 and .30 kg/m 2 , respectively) and their complications (especially type 2 diabetes, cardiovascular diseases, obstructive sleep apnea, osteoarthritis, male and female infertility, and certain forms of cancer) has greatly increased among adults and children. It has become an alarming medical and social issue 1 resulting from socioeconomic and behavioral changes in modern society (leading to increased energy consumption and decreased energy expenditure), 2 and biological factors. 3 Weight loss of 5%-10% of initial body weight reduces cardiovascular and metabolic health risks associated with obesity. 4 International Health Guidelines 4,5 recommend lifestyle modification as the first strategy in the management of obesity. If lifestyle modification alone is ineffective, pharmacotherapy may be considered for individuals with a BMI $ 30 kg/m 2 or for those with a BMI $ 27 kg/m 2 with comorbidities (eg, hypertension, diabetes, obstructive sleep apnea, type 2 diabetes) or a family history of overweight. Bariatric surgery should be reserved for individuals with a BMI $ 40 kg/m 2 or $35 kg/m 2 and comorbidities who do not lose weight with lifestyle modification and pharmacotherapy. 4, 5 Very recently, US Food and Drug Administration has approved the use of Allergan's LAP-Band Adjustable Gastric Banding System for people with a BMI . 35 kg/m 2 without comorbidities or for .30 kg/m 2 and at least one comorbidity.
Several studies have shown that the different antiobesity drugs, in conjunction with lifestyle treatments, can induce a weight loss up to 5%-10%, even if there is a great variability in individual response to a specific treatment. [7] [8] [9] Several different treatments, based on lifestyle modifications, [10] [11] [12] drugs, 13 and surgery 14, 15 have been developed in the past, and some others are currently being studied. 13 The investigation for factors responsible for obesity onset and response to antiobesity treatments started in the early 1960s, 16, 17 and the number of studies in this field has multiplied over the years. Most studies showed a wide variability in inter-individual response to all kinds of treatments, 18 a usually modest result in weight loss and maintenance, 19 and the involvement of many environmental, genetic, and behavioral factors. [19] [20] [21] [22] [23] However, predictors of outcome continue to be poorly understood. Availability of good predictors would allow physicians to match treatment to patients, and would improve cost-efficacy and patient's chances of success in losing and maintaining weight. 22, 23 This article focuses on factors that have been suggested as possible predictors of weight loss and/or weight maintenance in patients treated with orlistat, diethylpropion, mazindol, sibutramine, and topiramate (Table 1 ).
Methods and study description
A literature search was performed using PubMed database entering the drug name "and weight loss" for drugs approved by the FDA specifically for weight loss (orlistat, phentermine, and diethylpropion); drugs previously approved by the FDA that have been recently withdrawn from the market (sibutramine, mazindol, and rimonabant); and drugs approved by the FDA for other indications that exhibit weight loss promoting effects (topiramate, bupropion, and zonisamide). We found articles focusing on predictors in patients treated only with diethylpropion, orlistat, sibutramine, mazindol, and topiramate. Some studies investigated treatment outcomes in patients treated with an association of phentermine and fenfluoramine but, because this compound is no longer available and no comparative data with each single drug exists, these articles have not been included. Additional relevant articles from reference lists were included.
Only articles focusing on adults were included. Absolute or relative weight loss was the only considered variable. Thirty-three studies investigating gender, anthropometric, demographic, psychological, behavioral, and hereditary characteristics, associated medical conditions and habits, 
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All studies included subjects with a $25 kg/m 2 of both genders, except for two 24, 25 including females only. Age ranged from 16 to 70 years. The number of patients included in the different studies ranged from 36 to 3277. The duration of the study varied from 8 to 208 weeks. Some included a run-in phase. [26] [27] [28] [29] [30] [31] The main characteristics of the patient sample and program of the considered studies are displayed in Table 2 .
Predictors associated with orlistat treatments
Orlistat is a semisynthetic derivative of lipstatin which irreversibly and selectively binds to pancreatic lipases, reducing fat absorption by approximately 30% (Table 3) . 32 The prescribed dose is 120 mg, three times/day with meals. A meta-analysis 33 including approximately 10,000 participants treated for at least 1 year, reported a mean placebo-subtracted weight loss of 2.9 kg. Abdominal pain, bloating, flatulence, oily stools, and diarrhea represent common adverse effects; severe liver injury is rare. 34 
Demographic variables
Only one study 35 investigated the impact of gender on weight loss, and found no significant difference in the percentage of initial body weight lost by males and females.
Psychological factors and eating behaviors
Orlistat weight loss was positively related to the traits 'order' (P , 0.05), 'deliberation' (P , 0.01), and 'self-discipline', included in the main personality factor conscientiousness 35 (which reflect the ability to have and to persist with a goal-directed and motivated behavior, hence to consider matters before acting, to be methodical, well organized, and self-disciplined). This suggests that people with a stronger personality and great conscientiousness can achieve higher levels of long-term compliance towards a high demanding treatment like orlistat, a characterized thrice-daily regimen, and dietary fat restriction. The importance of determination on treatment's results is evident in European prescribing information 36 that, based on several observations, 26 orlistat is only recommended to those patients who have previously lost at least 2.5 kg by diet alone in a 4-week period, as an indication of their capacity to comply with prescribed dietary changes. Conversely, levels of restrained eating, anxiety, and depression showed no impact on the final outcome. 35 
Diabetes
Two studies 30, 37 pointed out the difficulty in losing weight experienced by diabetic patients treated with orlistat.
initial weight loss
A study conducted on 229 patients who completed a 2-year treatment 26 showed that people who lost $5% of their initial weight in the first 12 weeks achieved better final results than people who did not (−11.9 ± 0.8% vs −4.7 ± 0.5%; P = 0.0001). This finding was confirmed by another study 38 in which .80% of patients who achieved $5% reduction in their body weight after 3 and 6 months maintained .5% weight loss and .50% achieved $10% weight loss after 12 months (P , 0.01). Accordingly, European 36 and National Institute for Clinical Excellence 39 prescribing guidelines, which recommend that only people who lose $5% of initial body weight after 12 weeks and $10% after 6 months should continue taking orlistat.
Associated dietetic and environmental factors
Pharmacist's support was shown to improve patient's persistence with orlistat therapy but it did not improve the total amount of weight loss. 40 The total daily calories assumed with diet (500 vs 1000 kcal/day) 38 did not have a marked impact on the overall clinical outcome of weight reduction (average weight loss 11.8 and 11.4 kg respectively), while a low fat, but also carbohydrate, consumption was essential to lose weight. 31 
Predictors associated with diethylproprion treatments
Diethylpropion is an amphetamine like analog currently approved by FDA for short-term weight loss. 9 A metaanalysis conducted on several studies in which patients were treated with diethylpropion 75 mg/day in combination with lifestyle treatment showed an average 3.0 kg of additional weight loss, compared with placebo. 9 Common side effects include central nervous system stimulation, dizziness, headache, insomnia, restlessness, mild increases in blood pressure, palpitations, mild tachycardia, mild gastrointestinal symptoms, and rash. 9 To our knowledge, only one study 41 focused on predictors of weight loss in patients treated with diethylpropion, showing no statistically significant effect of patients' personality on weight loss, but just a positive correlation between social conformity and treatment completion (P , 0.004).
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Notes:
1 Cases: patients who had received a prescription for sibutramine in response to priori authorization through their health care insurer (PAR). Controls: subjects who did not receive reimbursement, although they were prescribed, sibutramine (non-PAR). Abbreviations: BL, sample characteristics at base line; BMi, body mass index (kg/m 2 ); BLCPCS, baseline characteristics of people who completed the study; Bw, body weight; C, Caucasians; F, number of female patients; eT, sample characteristics at the end of the program; mA, mean age; mBMi, mean body mass index (kg/m 2 ); mBw, mean body weight; Oe, other ethnicity; p, number of patients; yr, years old; LCD, low-calorie diet.
Predictors associated with sibutramine treatments
Sibutramine is a centrally-acting drug that reduces energy intake and increases satiety mainly through the inhibition of serotonine and norepinephrine reuptake (Table 4) . 8 Weight loss is enhanced by the stimulation of thermogenesis 42, 43 and the delay in gastric emptying. 44 The prescribing dose was 10-15 mg once daily. A recent meta-analysis 33 that included 2,838 participants treated with sibutramine for at least 1 year, showed a mean placebo-subtracted weight loss of 4.2 kg.
The drug was withdrawn from the market in October 2010 because of cardiovascular side effects. 13 
Psychological factors and eating behaviors
A study in 2003 27 demonstrated that patients with more deviating levels (elevated or lowered from the mean) of physical demand states (inborn and natural primary drives, including hunger) and dependency orientation (which implies preoccupation with oral activity such as eating and dependency on food, and which is typical of 
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Predictors of outcome in pharmacological antiobesity treatments people vulnerable to social isolation) lost more weight when treated with sibutramine (r = 0.533, P = 0.002 and r = 0.478, P = 0.008, respectively). Initial signs of difficulties concerning physical demand states were strong positive predictors of weight loss (r = 0.533, P = 0.002), explaining 27% alone. These findings suggest that the drug could improve conscious control over instinctual drives; alternatively, it could increase the sensitivity to alterations in hunger and satiety, helping people with initial high levels of hunger urges to improve control on food intake. The enhanced satiety effect of sibutramine could also have helped patients with high oral dependency to give less importance to food and the support provided by being enrolled in a treatment program could have helped them to abstain from food.
In the same study, 27 self-inspect ability (which means an ability to monitor and reflect on one's behavior and thinking) was related to weight loss but was not a predictor.
Several studies 24, 28, 35 have found that patients with more unrestrained eating (less cognitive control and conscious determination to resist eating, less strategic dieting) achieved greater weight loss, suggesting a negative influence of a pre-trial weight suppression on the subsequent treatment with sibutramine. 24 At the same time, the increase in dietary restraint and the decrease in disinhibition score during weight reduction phase guaranteed the success of weight loss maintenance. 24 Discordant results were obtained about the role of depression on weight loss. Two studies 27, 28 pointed out no correlations between depression and weight loss; two found a negative association between depression and weight loss; 24, 45 one 35 showed depression as a positive predictor (r = 0.40, P , 0.05).
Demographic and anthropometric factors
Except for one study that pointed out a positive association between younger age and weight loss, 35 age, 27, 45, 46 and gender 27, 46 appeared to be unrelated to the ability to lose weight. According to the only study that considered the influence of race on weight loss, 45 Caucasian ethnicity appeared a positive predictor (odds ratio [OR]: 0.42, P = 0.003). Two authors 35, 46 speculated that patients with higher pre-treatment body weight could achieve greater weight loss (r = 0.27, P , 0.001) because of their higher energy expenditure (resting metabolic rate) (r = 0.13, P = 0.003). 46 Conversely, another study 27 found no association between initial weight and weight loss at 6 months (r = −0.220, P = 0.242).
Familial obesity and personal weight history
One study 27 pointed out the positive effect that the absence of familial obesity and having been normal weight at some points as an adult had on weight loss, even if these factors were not statistically selected as predictors (Student's t-value = 3.239, P = 0.003; Student's t-value = 2.194, P = 0.037 respectively). Conversely, Fabricatore et al 45 obtained better results treating patients with a longer history of overweight. Hansen et al 46 showed the number of previous slimming attempts and the age of onset of obesity had no influence on final weight loss.
initial weight loss under treatment
Several studies 24, 27, 29, [45] [46] [47] [48] showed that early adherence to the program, early weight loss in the lead-in period and in the first 4 weeks of treatment were the strongest positive predictors of weight loss and maintenance, both in diabetic and nondiabetic patients. Accordingly, sibutramine prescribing guidelines submit your manuscript | www.dovepress.com
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Guaraldi et al 27 Fabricatore et al 45 Finer et al 29 Hainer et al 24 Hansen et al 46 PPwL: great initial weight loss PPwL: early adherence and weight loss PPwL: high early weight loss ($4 kg at 3 months) PPwL: high initial weight loss PPwL: high initial weight loss in the run-in period; high initial weight loss under treatment ntPwL: number of previous slimming attempts; age of onset of obesity van Baak et al 48 Grudell et al Predictors of outcome in pharmacological antiobesity treatments recommend physicians to increase the dose to 15 mg/day or discontinue treatment in patients who have not lost 2 kg in the first 4 weeks of treatment with the dose of 10 mg, and to avoid treatment beyond 12 weeks in people who fail to lose 5% of their initial body weight.
Genetic factors
Some authors focused on the effect that several genetic polymorphisms could have on weight loss and maintenance. Frey et al 50 investigated the role of the G . A transition at position −1211 of the human G protein α-subunit gene (GNAS) promoter, showing that sibutramine was effective only in A carriers (P = 0.002) (GG genotypes showed no additional weight loss under sibutramine compared to placebo). G protein α-subunit is responsible for hormones coupling to the enzyme adenylyl-cyclase and is required in adipocytes for the lipolytic response to β adrenergic agonists. 50 Four studies investigated GNB3, which encodes for the Gβ3 subunit of heteromeric G proteins (coupled to specific receptors, including serotonine and norepinephrine), key components of intracellular signal transduction, with a prominent role in body weight regulation. C825T (rs5443) polymorphism on exon 10 reduces lipolytic response to cathecolamines in fat cells 51, 52 and is associated with obesity, hypertension, and diabetes. Hauner et al 53 showed that sibutramine treatment was more effective in individuals with the CC genotype than in subjects with the TT/TC genotypes (weight loss: 7.2 ± 2.2 vs 4.1 ± 2.1 kg, P = 0.0013). In the CC group, the OR for a weight loss .5% (sibutramine vs placebo) was 6.6 (P = 0.004) and for a weight loss .10% was 9.6 (P = 0.010). This was in contrast with two studies 47, 54 showing that patients with TT/TC genotypes achieved better results than CC genotype (P = 0.018 and P , 0.001 respectively), and another study 44 pointing out no association between GNβ3 polymorphisms and weight loss.
One study 25 focused on the positive association (P = 0.003) between weight loss and the homozygous variant (either G/G or A/A) G148A of PNMT (phenylethanolamine N-methyltransferase) encoding for an adrenal enzyme catalyzing the conversion of norepinephrine to epinephrine 55 but, in a second study, this result was not confirmed. 44 Vazquez-Roque et al 44 investigated also the role of "short" (S) and "long" (L) repeats in the 5-HTT-linked region of the promoter of gene SLC6A4 (solute carrier family 6, member 4; chromosome 17q11.1-q12) encoding for the soluble serotonin transporter 56 and pointed out the positive effect of SLC6A4 LS/SS genotype on weight loss (subjects with SLC6A4 LS/SS genotype had an average weight loss of 6.1 ± 1.0 kg, compared with a 0.1 ± 0.9 kg average weight increase with placebo; subject with SLC6A4 LL genotype showed an average weight loss of 3.3 ± 1.8 kg on placebo, compared with 3.9 ± 1.6 kg weight loss in sibutramine group).
Grudell et al 47 found the positive effect of the association of TC/TT genotype of C825T polymorphism of GNβ3 gene and the CC genotype of α2A adrenoreceptor C1291G polymorphism or the 5HTTLPR LS/SS genotype.
Very recently, Hsiao et al 57 used the same patients in which they had investigated the role of GNβ3 polymorphism 54 to study the role of −866G/A polymorphism on weight loss in patients treated with sibutramine. The uncoupling protein 2 (UCP2) gene encodes a mitochondrial transporter protein, which is highly expressed in adipose tissue, skeletal muscle, and pancreatic islets. 58 A strong effect of sibutramine on weight loss was observed in individuals with the AA, GA, and AA + GA genotypes (P = 0.019, P , 0.001, and P , 0.001, respectively) whereas the drug caused no significant effect in individuals with the GG genotype (P = 0.063). For the combination of UCP2 AA + GA with GNβ3 TT + TC (carriers of at least one variant allele for each polymorphism), the P-value for treatment effects on weight loss was ,0.001. In contrast, no effects were observed in patients with the wild type genotype combination of UCP2 GG and GNβ3. A significant (P , 0.001) gene interaction between UCP2 and GNβ3 was identified by a 2-locus model.
Associated pathologies, habits, nutritional, and environmental factors
Diabetes represents the chronic disease that most often is associated with obesity. Weight loss improves glycemic control and can be achieved using pharmacological therapy. 30, 37, 59 However in diabetic patients weight management is more challenging, in part because of the weight-promoting effects of the majority of anti-diabetic drugs 37 and, on average, is achieved slower and less (up to 69%) than in nondiabetic patients. 29, 30, 37, 59 This final aspect is recognized by the Australian regulatory authorities who suggest to withdraw sibutramine after 3 months in nondiabetic patients who have failed to lose 5% of their initial body weight but after 6 months in diabetic patients. 60 On the other side, estrogen levels (ie, menopause, hormone replacement), hysterectomy, 25 and smoking habit 46 were demonstrated to not have a significant effect on weight loss in response to sibutramine. The addition of behavioral therapy 45 or high leisuretime physical activity 48 to sibutramine showed a strong favorable effect on weight loss and maintenance, while dietetic modifications in fat, protein, and fiber intake 24, 25 during the treatment, and the choice of 8 vs 12 months period of treatment 24 did not have a great impact on outcomes. This is in accordance with most of studies on antiobesity drugs that demonstrate that the maximum weight loss is achieved after 6-8 months, whereas after 12-16 months of treatment, minor weight regain usually occurs. 61, 62 A priori authorization to have sibutramine partially reimbursed improved patients' compliance and weight loss. 63 Distance to the clinic was marginally related to treatment success. 45 
Predictors associated with mazindol treatments
Mazindol is a centrally acting drug that blocks the reuptake of norepinephrine by presynaptic neurons, increasing norepinephrine levels within the synaptic cleft ( Table 5 ). The result is the stimulation of the β2 adrenergic receptors in the lateral hypothalamus and the inhibition of feeding. 11 It also inhibits gastric acid and insulin secretion, and increases locomotor activity. 64 
Psychosocial factors and eating behavior
A study in 1977 41 found that high social conformity and emotional stability, extraversion, and need for social acceptance improved patients' adhesion to the program, whereas no personality characteristic predicted weight loss.
According to a more recent study, 65 high levels of hunger, anxiety, and dietary restraint, and small perceived body size had a negative influence on weight loss in patients treated with mazindol. Suggested explanations for these findings were the drug incapability of controlling extreme levels of hunger, the limited slimming possibility in patients dieting before entering the treatment, and the individual lacking perception of the need for weight loss.
Genetic factors
Two studies 66, 67 pointed out a significantly greater body weight reduction in subjects with the Trp64 Trp allele than in those with Trp64Arg allele of ADRβ3 gene (encoding for a protein which regulates cathecolamine-induced lipolysis 68 mainly expressed in white adipose tissue) (6.9 ± 1.0 kg vs 3.6 ± 0.7 kg in the first study and 8.4 ± 1.7 kg vs 3.7 ± 0.8 kg in the second study; P , 0.05).
Predictors associated with topiramate treatment
Topiramate is an anticonvulsant drug acting on sodium and calcium T-type channels ( Table 6 ). The way in which it could promote weight loss is still unknown. Some authors have shown an increase in extraneuronal levels of dopamine, norepinephrine, and serotonin in the hippocampus and have speculated that a similar effect in the hypopthalamus could explain topiramate action as an appetite suppressor. 69 Other studies have demonstrated an increase in fat metabolism (through the increased activity of lipoprotein lipase in adipose tissue and promotion of hepatic fat metabolism and decreased fatty acid synthesis) 70, 71 and the inhibition of lipogenesis through the inhibition of carbonic anhydrase II and V. 72 A recent meta-analysis 9 based on studies conducted on epileptic patients reported an average placebo-subtracted weight loss of 6.5% in topiramate-treated patients (P , 0.001). Adverse effects are paresthesia, changes in taste, dizziness, memory impairment, insomnia, and somnolence.
9,73
Demographic and anthropometric factors
Three studies [74] [75] [76] pointed out a correlation between higher initial BMI and a greater weight loss (P , 0.001) in epileptic patients treated with topiramate for a period of 10 weeks to 6 months. Only one study 77 conducted on migraine patients treated for 4 months found no correlation between initial BMI, gender, and total weight loss (P = 0.44). 
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One study 76 reported a positive (P = 0.002) association between a reduction in hunger after 3 months of treatment and total weight loss at month 6.
Results
Our analysis pointed out the overall paucity of reliable predictors of weight loss and maintenance associated with pharmacological antiobesity treatments, a characteristic previously described by studies focusing on lifestyle modification treatments. 18, 19 Indeed, among all considered factors, the early response to treatment was demonstrated to be a sure positive predictor of weight loss and maintenance. Conversely, diabetes appeared to have a strong negative impact on patients' ability to lose weight when treated with the different drugs.
A more unrestrained eating at baseline and high levels of determination and self-discipline appeared to be positive predictors of outcome in patients treated with sibutramine and orlistat, respectively, even if the statistical association was less strong.
For all other considered variables, published data are not sufficient to define their role on final outcomes.
Conclusion
Limitations related both to the disease and to the intervention program could explain these inconclusive and often conflicting results. Indeed, the multitude of factors involved in obesity's development and weight loss, and their complex interactions make each patient different from the other and the investigation of reliable predictors particularly challenging. Furthermore psycho-behavioral difficulties experienced by patients when starting a new treatment, and the lack of significant results often associated with the different therapies, are responsible for the high levels of attrition of patients from the weight-loss programs.
At the same time, our analysis pointed out important limitations related to currently available literature investigating outcomes associated to antiobesity pharmacological treatments. First of all, few studies have been conducted with the primary aim to point out the role of specific factors on weight loss and maintenance. Second, a minor part of these studies have included a large cohort of patients. Third, studies are very heterogeneous from the point of view of the number and characteristics of patients included, the duration and type of program, and the tests and parameters used for patients' evaluation. Finally, very often, the analysis and interpretation of the achieved results are very difficult and the power of the associations is reduced because of the limited number of subjects included.
Probably, the enrollment of a greater number of patients in future trials, the use of common protocols of treatment and parameters (for each category of predictors) to assess final outcomes could improve statistical significance of results and the ability to compare data. Moreover, because both obesity onset and weight loss are dependent on the interaction of a great number of different factors, it could be important to test different categories of predictors on the same group of patients.
Despite the above mentioned difficulties and the discouraging results obtained until recently, we believe that, because of obesity's social and medical impact and the availability of new promising antiobesity drugs (whose mechanisms of action are very often similar to those of old drugs; the most promising one is the association of bupropion and naltrexone), 79 the search for reliable predictors of o utcome associated to antiobesity treatments has to be supported and encouraged.
Being able to find reliable predictors of successful outcome for pharmacological treatments would mean to give prescribing physicians, patients, and the authorities a tool for antiobesity drug management. 
